Background. Intermittent regimens offer operational advantages in tuberculosis treatment, but their efficacy has been questioned. We updated a systematic review and metaanalysis to examine the efficacy of different intermittent dosing schedules in firstline pulmonary tuberculosis therapy.
Over the past 3 decades, intermittent therapy has been widely used in first-line tuberculosis treatment. This dosing strategy reduces medication and healthcare worker costs for tuberculosis programs and has facilitated global scale-up of directly observed therapy [1] [2] [3] . Various intermittent dosing regimens for tuberculosis treatment have been recommended in more than 130 countries [4] . Unfortunately, high rates of relapse and acquired drug resistance have been noted in trials and tuberculosis programs that use intermittent therapy [2, 3, 5] . Since 2008 the World Health Organization (WHO) has recommended a daily regimen as the preferred dosing schedule for all tuberculosis therapy [6] . However, intermittent regimens continue to be an option in several national tuberculosis guidelines [7, 8] and, until recently, was the recommended treatment schedule in some high-incidence regions [4, 9] .
Previous systematic reviews have examined outcomes of different dosing schedules [2, 3, 5, [10] [11] [12] [13] , including a 2009 systematic review by Menzies et al that compared daily therapy to 3 intermittent dosing schedules [5] . In this analysis, thrice weekly therapy throughout treatment and twice weekly therapy in the intensive phase were both associated with a nonsignificant increase in failure, relapse, and acquired drug resistance. Thrice weekly dosing throughout therapy was also associated with a higher rate of acquired drug resistance in metaregression. These results, though not statistically significant, pointed toward daily therapy as the preferred regimen for first line tuberculosis therapy.
Since 2009, several high-quality randomized, control trials (RCTs) have been published that used the first-line WHO standard treatment regimen [14] [15] [16] [17] [18] [19] [20] . These data have offered an opportunity to update our metaanalysis of the effect of intermittency on first line tuberculosis treatment outcomes.
We performed an update from the 2009 systematic review performed by Menzies et al [5] to address the following question: What are the rates of treatment failure, relapse, and acquired drug resistance with the different dose administration schedules?
METHODS
In this review, we followed methods described in the PRISMA statement for reporting of systematic reviews and metaanalyses [21] (see PRISMA checklist in Supplementary Material).
Search Strategy
In the original review, a search of PubMed, Embase, and the Cochrane Library was performed for the period 1965 to June 2008 and reported in detail elsewhere [5] . We performed an updated search in the same 3 electronic databases from 1 June 2008 to 15 March 2016. Our search was restricted to RCTs that reported treatment outcomes in first-line pulmonary tuberculosis therapy. We included publications in English, French, and Spanish. We examined the references of all full text results, recent treatment guidelines, and prior systematic reviews for relevant studies not captured by the previous search strategy. Two authors (J. C. J., J. R. C.) reviewed titles, abstracts, and full text articles for inclusion.
Study Selection
We included RCTs that reported tuberculosis treatment outcomes of failure, relapse, and/or acquired drug resistance. Only data on new patients (ie, not previously treated) were included. Consistent with current WHO recommendations, we included only studies with treatment regimens that used rifampin for 6 months or longer (this criterion was added since the last review). Arms with drug-susceptible strains or unknown drug susceptibility (ie, smear only) were included (this criterion was added since last review). Trial arms that included rifapentine, rifabutin, second-line therapies, or nondrug therapy were excluded. We also excluded trial arms that involved once-weekly or monodrug therapy at any point in the study.
Data Extraction and Quality Assessment
Consistent with the original review, we restricted studies to high-quality RCTs. To be considered high quality, studies had the following features: bacteriologic confirmation of initial diagnosis (through microscopy or culture), bacteriologic confirmation of failure, and/or relapse; fewer than 10% of patients refusing therapy, dropped out, moved away, or were otherwise unaccounted for during therapy; and use of concealed allocation during randomization.
Outcome Definitions
Treatment failure was defined as sputum smears and/ or cultures consistently positive at the end of therapy or ≥5 months of therapy [22] . Relapse was defined as positive smears and/or cultures that required therapy after treatment success (completion or cure). In the presence of genotyping data, individuals with genotypic evidence of reinfection were not counted as relapse. Acquired drug resistance was defined as new or additional resistance to 1 or more tuberculosis drugs received among those who failed or relapsed.
Outcomes were obtained from per protocol analysis when available. Participants who did not complete therapy because of drug reaction, treatment noncompletion, and death were not included in analysis.
Statistical Analyses
We performed 2 types of analysis for this study. In the first metaanalysis, we pooled the risk differences for treatment failure, relapse, and acquired drug resistance in RCTs with head-to-head comparisons of different intermittency schedules. Only 1 study that reported head-to head comparisons was identified, so this planned metaanalysis was not performed.
In the second analysis, we combined data from all studies using a random effects model (procedure NLMIXED in SAS version 4.3) with the exact binomial likelihood approach to calculate the pooled proportion, 95% confidence interval (CI), and test for significant differences in outcomes of treatment failure, relapse, and acquired drug resistance by rifampin intermittency schedule [23] . Effectively, each RCT arm was treated as an individual cohort, and the proportion of each outcome was pooled to estimate an overall pooled effect estimate of proportion of each outcome by 1 of 4 predefined intermittency schedules: daily throughout (defined as dose administration ≥5 days per week), thrice weekly throughout (defined as dose administration 3 times per week throughout therapy); daily then twice weekly (defined as daily [≥5 days per week] in the intensive phase, then 2 times per week in the continuation phase); and daily then thrice weekly (defined as daily [≥5 days per week] in the intensive phase, then 3 times per week in the continuation phase). We did not analyze studies with twice weekly throughout therapy given the limited data on this regimen.
Multivariate Analysis
We performed metaregression to examine outcomes of failure, relapse, and acquired drug resistance after adjusting for relevant predefined covariates. Two models were developed. The first model included the covariates of dosing schedule, duration of pyrazinamide, duration of streptomycin, number of drugs to which the organism was susceptible in the intensive and continuation phase, supervision of therapy, proportion with default, and length of follow-up (for relapse, acquired drug resistance, and combination relapse-failure outcome). Due to the high correlation between initial drug resistance and the number of drugs to which the organism was susceptible to in the intensive and continuation phases, the second model did not include the number of susceptible drugs used but instead included the initial drug resistance profile as a covariate. Metaregression was performed using negative binomial regression in Stata (version 12.0) [23] . In this metaregression, the arms of each study were the unit of analysis; the cumulative proportion of tuberculosis treatment outcomes was the dependent variable, and tuberculosis treatment characteristics were the independent variables. An offset was used to account for study size. Effect estimates were interpreted as adjusted incidence rate ratios, and the significance of each factor in the models was evaluated using the log likelihood ratio test [24] .
Assessment of Heterogeneity and Bias
We assessed heterogeneity of risk differences for each comparison by estimating the I 2 statistic and associated 95% CIs.
For this calculation, studies in which both treatment arms had no events were corrected by 0.5. We assessed bias by generating funnel plots for the proportion of each outcome (failure, relapse, acquired drug resistance) in the primary analysis.
Primary and Sensitivity Analysis
For our primary outcome, we performed metaanalysis and metaregression on all trial arms with rifampin duration ≥6 months. We included individuals with smear or culture positivity with a pan-sensitive strain or an unknown susceptibility profile to reflect care in many low-resource settings. We included studies with rifampin duration ≥6 months to reflect the current WHO standard. We performed similar analyses in several subsets of the study arms; trial arms with confirmed drug-susceptible disease (with and without streptomycin resistance); trial arms without any patients with known human immunodeficiency virus (HIV) infection; trial arms with drug-resistant isolates; and trial arms that used 2 months of isoniazid (H), rifampin (R), pyrazinamide (Z), +/-ethambutol (E), followed by 4 months of HR +/-E (abbreviated as 2HRZ(E)/4HR(E)). Significantly different from reference at P < .05. c In all but 1 trial, if therapy was intermittent initially, the same schedule was continued throughout therapy. Significantly different from reference at P < .01.
e In a few trials, the number of drugs was the same throughout-these were classified according to the starting regimen.
RESULTS

Study Selection and Assessment
After removing duplicates, 5874 citations were identified from the updated search. Of these, 546 studies were retained for abstract review and 105 for full text review. An additional 3 full text studies were identified from the reference search, resulting in 108 publications for full text review. After full text review, 7 RCTs were included for analysis ( Figure 1, Table 1 ), adding 3338 participants from 10 trial arms. This included 5 arms that reported results of daily therapy, 2 arms that reported daily followed by intermittent therapy, and 3 arms that reported intermittent therapy throughout treatment. All updated studies involved adults and reported at least 1 arm with the standard WHO first-line treatment regimen of 2HRZE/4HR(E).
After combining the results of the original search strategy and limiting inclusion to only studies that used ≥6 months of rifampin in a strain with an unknown susceptibility profile or that was pan susceptible, the updated systematic review included 56 RCTs with 110 arms; 8 RCTs from the original analysis were excluded from analysis ( Figure 2 ). The outcomes of failure were examined in 108 arms with 13 401 participants; relapse was available for 105 arms with 12 184 participants; and acquired drug resistance was available for 83 arms with 7443 participants. The updated literature search yielded no studies that examined intermittency schedules in head-to-head comparison and only 1 study with 223 patients that reported on daily vs twice-weekly therapy from the prior search.
Pooled Results Across Studies
We pooled results from the 110 arms that reported treatment outcomes from regimens with ≥6 months of rifampin in arms b Significantly different from reference at P < .01.
c In all but 1 trial, if therapy was intermittent initially, the same schedule was continued throughout therapy.
d Significantly different from reference at P < .05.
with strains that were pan susceptible or did not undergo DST. Four administration schedules were analyzed, with outcomes from primary analysis reported on 64 arms with 8839 participants in daily therapy; 19 arms/2310 participants with thrice weekly throughout; 18 arms/2075 participants with daily then thrice weekly; and 9 arms/793 participants with daily then twice weekly ( Figure 2 ). The pooled proportions of participants with failure, relapse, and acquired drug resistance by drug intermittency schedule are listed in Tables 2-4 . There was a significant increase in the pooled proportion of participants with relapse in those receiving thrice weekly (6.8; 95% CI, 3.8-9.9) and daily then twice weekly (7.3; 95% CI, 3.5-11.1) compared with daily therapy throughout (2.5; 95% CI, 1.8-3.2; P < .01). Participants who received daily then twice weekly therapy also had an increase in pooled proportion of failure (1.3; 95% CI, 0-2.9) compared with those who received daily throughout (0.2; 95% CI, 0.1-0.4; P < .05). There was no significant difference in the proportion of participants with acquired drug resistance regardless of administration schedule.
Metaregression
After adjusting for the potentially confounding treatment factors described above, participants who received thrice weekly therapy throughout had significantly higher incidence rate ratios (IRRs) for failure (3.7; 95% CI, 1. b In all but 1 trial, if therapy was intermittent initially, the same schedule was continued throughout therapy.
c In a few trials, the number of drugs was the same throughout-these were classified according to the starting regimen.
Sensitivity Analysis and Assessment of Bias
Results of several analyses are presented in Supplementary Material. Given the concern over the effect of HIV on intermittency outcomes, we aimed to pool data on intermittency by HIV status. Unfortunately, data on HIV-infected individuals were incompletely reported; 9 arms examined outcomes in only HIV-infected populations, while 15 arms reported >10% HIV prevalence in study participants. Overall, there were too few studies with HIV-infected participants to examine pooled proportion of treatment outcomes or perform metaregression by HIV proportion. We performed an analysis that excluded arms with any HIV-infected participants to assess the effect on pooled outcomes. In metaregression of this population, the pooled proportion of relapse and acquired drug resistance were significantly higher, while there was a nonsignificant increase in the failure rate (see Supplementary Material). After accounting for the low proportions for each outcome, visual inspection of the funnel plots revealed no imbalances consistent with publication bias (see Supplementary Material).
DISCUSSION
In this updated review in which the effect of intermittency on first-line pulmonary tuberculosis treatment outcomes was examined, we found a significant increase in microbiologically defined adverse outcomes in participants who received thrice weekly therapy throughout treatment. This finding was maintained after we accounted for potential confounding variables in metaregression and on multiple sensitivity analyses that varied by susceptibility profile, treatment regimens, and HIV status. The evidence against intermittent therapy in the continuation phase was less clear. Daily therapy in the intensive phase followed by twice weekly therapy appeared to have worse outcomes than daily therapy throughout, with higher rates of failure and relapse in pooled analysis and a significant increase in failure in metaregression. Meanwhile, thrice weekly therapy in the continuation phase showed a nonsignificant increase in relapse in pooled analysis but without a clear signal toward worse outcomes in metaregression. Our findings build on evidence from recent systematic reviews and modeling studies to argue against intermittent dosing throughout first-line pulmonary tuberculosis therapy [2, 3, 5, 11] . A previous systematic review performed by members of our group demonstrated an increase in the pooled proportion of relapse without a statistically significant increase in failure or acquired drug resistance [5] . Similarly, in their systematic review of RCTs and cohort studies, Kasozi et al reported a significant increase in relapse compared with daily therapy but did not evaluate other microbiologic treatment outcomes [11] . Lastly, Chang et al demonstrated an increase in relapse in a systematic review and modeling study in which they examined different therapy schedules [3] .
Our review has several strengths. We examined data from 56 RCTs spanning several decades and resource settings. The RCTs we examined were considered high quality with comprehensive reporting and robust, microbiologically confirmed treatment outcomes. We found similar outcomes in multivariate analysis and numerous sensitivity analyses that varied by patient population, susceptibility profiles, and treatment regimens.
Our study also has several limitations. First, similar to the 2009 systematic review, we found only 1 trial that examined head-to-head comparisons of rifampin intermittency [5] . The absence of head-to-head comparisons increases the potential for confounding by patient, strain, and treatment characteristics, as the randomization performed in each RCT did not apply to dose schedule itself. The absence of comparisons between dosing schedules also precluded network metaanalysis, which requires multiple pairwise comparisons between treatment regimens for robust analysis [25] . In our case, the limited number of comparisons between dosing schedules and the limited sample size within each comparison arm would have limited this analytic technique. Instead, we performed metaregression to control for potential confounding covariates.
In addition, many of the studies were performed before 1980, when treatment regimens, HIV prevalence, and programmatic characteristics were substantially different from today. We attempted to control for this deficiency by examining studies with WHO-recommended treatment regimens in order to reflect more modern tuberculosis treatment and in order to compare outcomes with and without streptomycin therapy. We are reassured by the results of these sensitivity analyses, which were largely similar to the outcomes of our primary analysis (Supplementary Material).
Finally, we did not examine treatment noncompletion and adverse events as treatment outcomes. Instead, we focused on more strictly defined, microbiologically confirmed treatment outcomes in an attempt to minimize between-study variability. Intermittent regimens were developed to overcome patient and programmatic barriers to therapy; these regimens offer less pill burden to patients, less potential for daily adverse events, and fewer barriers to programmatic implementation of directly observed therapy [1] . Consistent with the programmatic benefits of intermittent therapy, a systematic review by Kasozi et al demonstrated decreased default with intermittent regimens compared with daily regimens throughout [11] . Their review included several cohorts, which are presumably more reflective of programmatic settings. In contrast, our analysis focused on data from high-quality RCTs with strictly defined, microbiologically confirmed treatment outcomes. Presumably, data obtained under RCT conditions reflect more idealized conditions, which may in turn result in improved adherence rates and may underestimate the benefits of intermittent therapy. We recognize that intermittent therapy may result in lower treatment noncompletion rates but also recognize that low noncompletion rates can be achieved in tuberculosis programs in a variety of resource settings. We do not believe that implementation of a less efficacious regimen to overcome programmatic deficiencies is necessarily a desirable approach.
CONCLUSIONS
This review provides evidence against the use of intermittent tuberculosis therapy throughout treatment, demonstrating that this type of intermittent regimen is inferior in all 3 outcomes measured on pooled analysis and metaregression. Likewise, twice weekly therapy in the intensive phase appears to be associated with worse outcomes, while thrice weekly therapy in the continuation phase does not appear to be clearly inferior but may have an increased risk relapse.
Despite the wealth of trial and operational data on the WHO standard 6-month treatment regimen, we still have much to learn about dosing of tuberculosis therapy. Adequately powered clinical trials that examine dosing schedules in first-line treatment of drug-susceptible tuberculosis are still needed to fully understand the impact of intermittency on tuberculosis treatment outcomes in first-line therapy.
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